Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.28 - $10.53
Previous CloseN/A
Volume1.20M
Average Volume (3M)5.59M
Market Cap
$2.40B
Enterprise Value$3.49B
Total Cash (Recent Filing)$143.43M
Total Debt (Recent Filing)$504.17M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding853,442,140
10 Day Avg. Volume4,208,743
30 Day Avg. Volume5,592,126
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)159.75
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit236.40
Enterprise Value/Ebitda-13.18
Forecast
1Y Price Target
$6.08Price Target Upside124.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
ImmunityBio News
PremiumCompany Announcements
ImmunityBio’s Sales Surge Amid Strategic Advances
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThere are several ongoing and planned studies evaluating ANKTIVA with cancer vaccines and natural killer cells in additional solid tumor indications, which could increase the stock value.
Market ExpansionImmunityBio is expanding its market penetration by filing a BLA for BCG-unresponsive papillary NMIBC, potentially yielding top-line results by late 2025/2026.
Strategic CollaborationThe exclusive global arrangement with the Serum Institute of India for the supply of BCG provides a key strategic advantage to ImmunityBio given the current BCG shortage.
Bears Say
Clinical RiskRisks to achieving the price target include clinical risk where ImmunityBio’s assets may fail to demonstrate meaningful levels of efficacy in clinical trials.
Product VariabilityBCG is an old and genetically unstable therapy susceptible to drift, leading to costly batch-to-batch variability.
Regulatory ChallengesThe FDA authorization for Expanded Access Program for recombinant BCG helps address one of the points of pushback for ANKTIVA's use and uptake in non-muscle invasive bladder cancer.
---
Ownership Overview
76.66% Insiders
2.65% Mutual Funds
2.22% Other Institutional Investors
14.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $2.28 and its highest was $10.53 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $2.40B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is May 08, 2025 which is in 46 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Mar 03, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.11.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.13.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 853,442,140 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -13.374%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
---
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.08 (124.35% Upside)
$6.08 (124.35% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $230.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.09%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-24.09%
Trailing 12-Months
Company Description
ImmunityBio
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
---
IBRX Stock 12 Month Forecast
Average Price Target
$6.08
▲(124.35% Upside)
Technical Analysis
Best Analysts Covering IBRX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
+17.86%
reiterated a buy rating 7 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +17.86% per trade.
---